Pharmaceutical Market Europe - June 2017

This month we have such a bumper issue of PME for you that it’s almost difficult to know where to begin.

Turning first to our Digital Disruption supplement we find an area where, as LEO Innovation Lab CEO Kristian Hart-Hansen notes, “the structure of our industry and the needs of our patients are now evolving at a much faster rate than they ever have before”.

Meanwhile, as the German pharma market looks set for stable, if not strong, growth over the next four years, it’s anyone’s guess how the latest twist in the UK’s political landscape will affect the industry over here.

What we can say with certainty is that European regulators won’t be waiting for the region’s politicians to thrash out a deal on the post-Brexit landscape. Instead the last month has seen concrete developments in the future shape of the regulatory environment, with a set of guidance now available.

We also take a look in the rear view mirror to check out how pharmaceutical products have fared with those regulators as compared to their US counterparts.

The signs are that Europe is holding up well with no drop in approval rates seen on this side of the pond. Unsurprisingly it’s both oncology and big pharma that have dominated over the last four years.